Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

This drug had not previously been considered by the PBAC for this indication. Osteoporosis must be confirmed by the finding of low bone mass of at least 2 standard deviations below the gender specific ...

BANGALORE, Sept 12 (Reuters) - India's Sun Pharmaceutical Industries said it has received approval from the U.S. Food and Drug Administration to market alendronate sodium tablets, the generic version ...

Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...

Please provide your email address to receive an email when new articles are posted on . Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for ...